<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720886</url>
  </required_header>
  <id_info>
    <org_study_id>G56W1A201</org_study_id>
    <nct_id>NCT03720886</nct_id>
  </id_info>
  <brief_title>G56W1 in Women With Postmenopausal Osteoporosis</brief_title>
  <official_title>Two-dose, Positive Drug Control, Multicentre, Randomized, Double-blind Study of Recombinant Human Parathyroid Hormone for Injection(rhPTH)(1-34) Once a Week to Treat Postmenopausal Osteoporosis Women for the Evaluation the Pharmacokinetics and Safety and to Explore Therapeutic Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Salubris Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Salubris Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics and safety and explore therapeutic effects with
      once-weekly recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 ) in women
      with post-menopausal osteoporosis .The anticipated time on study treatment is 24 weeks, and
      the target sample size is 148 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage change in bone density of the lumbar spine ( L1-4 ) from baseline to 24 weeks after treatment</measure>
    <time_frame>Baseline，week 24</time_frame>
    <description>bone mineral density(BMD) measured by dual energy x-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the rate of change of Procollagen I N-terminal peptide(PINP),Serum cross-linked C-terminal telopeptide of type I collagen(s-CTX) ,Bone alkaline phosphatase(BALP) , and blood calcium from baseline</measure>
    <time_frame>Baseline，week 24</time_frame>
    <description>Central lab will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage change of total hip bone density from baseline to 24 weeks after G56W1 treatment</measure>
    <time_frame>Baseline，week 24</time_frame>
    <description>BMD measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Baseline，week 1，week 4，week 12，week 24</time_frame>
    <description>serum parathyroid hormone(PTH) will be tested for all pharmacokinetics parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Baseline，week 1，week 4，week 12，week 24</time_frame>
    <description>serum PTH will be tested for all pharmacokinetics parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration（Tmax）</measure>
    <time_frame>Baseline，week 1，week 4，week 12，week 24</time_frame>
    <description>serum PTH will be tested for all pharmacokinetics parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life（t1/2）</measure>
    <time_frame>Baseline，week 1，week 4，week 12，week 24</time_frame>
    <description>serum PTH will be tested for all pharmacokinetics parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>rhPTH（1-34） 28.2μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 28.2μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhPTH（1-34） 56.5μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 56.5μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teriparatide acetate(Teribone™)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rhPTH（1-34） 28.2μg</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>rhPTH（1-34） 28.2μg</arm_group_label>
    <other_name>G56W1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rhPTH（1-34） 56.5μg</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>rhPTH（1-34） 56.5μg</arm_group_label>
    <other_name>G56W1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>teriparatide acetate(Teribone™)</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>teriparatide acetate(Teribone™)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, capable of self - motivation , 45 years old ≤ age ≤ 75 years old.

          -  Natural menopause for 3 years or more; or surgical menopause for 3 years or more
             (surgery needs to be performed after 40 years old), for women with surgical menopause,
             estradiol(E2)&lt; 25 pg/ml and follicle stimulating hormone(FSH) &gt; 40mIU/ml should be
             met.

          -  Weight ≥ 40kg , 18 ≤ body mass index(BMI)≤ 30 .

          -  Meets one of the following diagnostic criteria for osteoporosis, and ≥ 3 vertebral
             bodies of L1-4 can be measured by bone mineral density using the DXA method.

               1. Brittle fracture of the hip or vertebral body, and the bone density measurement
                  T- score&lt; -1.0.

               2. The T- score of the central axis bone mineral density or the 1/3 bone density of
                  the distal radius of the tibia was ≤-2.5 measured by DXA .

               3. Bone density measurements were consistent with low bone mass ( -2.5 &lt; T- value &lt;
                  -1.0 ) and combined with proximal humerus, pelvic or forearm distal brittle
                  fractures.

          -  to participate in the trial and sign the informed consent form.

        Exclusion Criteria:

          -  to have diseases affecting calcium or bone metabolism that are not effectively
             controlled, such as primary hyperparathyroidism or hyperthyroidism, Paget's bone
             disease, hypercalcemia, hypocalcemia, active urolithiasis.

          -  Secondary osteoporosis, such as osteomalacia, rheumatoid arthritis, gout, multiple
             myeloma, etc.

          -  Severe lumbar anatomical abnormalities which affecting DXA bone mineral density
             measurement, such as severe scoliosis.

          -  Patients who have been treated for anti-osteoporosis before random enrollment:

               1. Patients who received parathyroid hormone(PTH) therapy before random enrollment
                  (including clinical trials of similar products).

               2. Patients who received bisphosphonate injection within 1 year prior to random
                  enrollment or received bisphosphonate oral administration within 3 months for &gt; 2
                  weeks prior to enrollment.

               3. Systemic treatment of androgen, estrogen, and selective estrogen receptor
                  modulator(SERM) preparations within 3 months &gt; 2 weeks prior to random
                  enrollment.

               4. Three months before randomized to receive of heparin, warfarin, anticonvulsants
                  (except benzodiazepines), digoxin accumulated for&gt; 2 weeks.

               5. In the 3 months prior to random enrollment , received calcitonin, vitamin K
                  preparation, active vitamin D3 preparation, oral or intravenous glucocorticoid
                  treatment for &gt; 4 weeks.

          -  Suffering from severe kidney disease, uncontrolled high blood pressure ( ≥150/100 mmHg
             ), symptomatic ischemic heart disease, cerebral infarction or obliterative
             atherosclerosis, malignancy, and other serious underlying diseases.

          -  Laboratory tests indicates abnormal, including any of the following indicators
             abnormalities (according to the normal range of each center, after consideration of
             the investigator with clinical considerations, such as caused by operational
             procedures, etc., after discussion with the sponsor, may allow retesting once) .

               1. Alkaline phosphatase(ALP)&gt;1.5 times the upper limit of normal.

               2. Aspartate transaminase(AST) or alanine aminotransferase(ALT) or total
                  bilirubin(TBIL) &gt; 2.0 times the upper limit of normal.

               3. Glycated hemoglobin(HbA1c )≥ 7.0% .

               4. White blood cell(WBC)&lt; 3.5×10^9 /L , Hb&lt;100g/L or Plt&lt;90×10^9 /L.

               5. Thyroid-stimulating hormone(TSH)&lt;0.01 mIU/L (mU/L) or TSH&gt;10 mIU/L (mU/L) .

               6. Parathyroid hormone(PTH)&gt;1.5 times the upper limit of normal.

               7. Serum creatinine(SCr)&gt;1.2 times the upper limit of normal.

               8. Serum total calcium(SCa)&gt; normal upper limit.

          -  Subjects who had significant clinical significance including HIV , hepatitis B,
             hepatitis C, and syphilis ( hepatitis B virus carriers can be enrolled ) .

          -  Heavy Smoking (average of more than 10 / day) and / or alcohol addicted (converted to
             pure alcohol 30 ml / day or more) .

          -  Recent drug abuse or drug dependence evidence.

          -  Those who are allergic to test drugs / control drugs or biological products.

          -  Included in other interventional clinical trials within 3 months of the study.

          -  Been undergone radiation therapy for bones.

          -  Mental illness or any cause of cognitive impairment.

          -  Patients who were considered unsuitable for the study based on risk benefits by
             investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weibo Xia, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Wanzhou</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huadong Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West China Second UniversityHospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

